<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04050462</url>
  </required_header>
  <id_info>
    <org_study_id>18-01028</org_study_id>
    <nct_id>NCT04050462</nct_id>
  </id_info>
  <brief_title>Nivolumab Combined With BMS-986253 in HCC Patients</brief_title>
  <official_title>A Phase II, Randomized, Controlled Trial of Nivolumab in Combination With BMS-986253 in Advanced Hepatocellular Carcinoma (HCC) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II clinical trial is utilized to examine whether BMS-986253 (25 subjects) or&#xD;
      Cabiralizumab (25 subjects) when combined with Nivolumab offers improved radiographic&#xD;
      objective response rates (ORR) over Nivolumab monotherapy (25 subjects) in advanced HCC&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2019</start_date>
  <completion_date type="Anticipated">August 5, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 5, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) of Cabiralizumab or BMS-986253 in combination with Nivolumab in comparison to Nivolumab monotherapy</measure>
    <time_frame>6 Years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Nivolumab Monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab/BMS-986253 combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab/Cabiralizumab combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks</intervention_name>
    <description>Nivolumab 240 mg IV plus Cabiralizumab 4 mg/kg IV every 2 weeks combination therapy</description>
    <arm_group_label>Nivolumab/Cabiralizumab combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks</intervention_name>
    <description>Nivolumab 240 mg IV plus BMS-986253 1200mg IV every 2 weeks</description>
    <arm_group_label>Nivolumab/BMS-986253 combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab 240 mg IV every 2 weeks</intervention_name>
    <description>Arm 1 (control) Nivolumab 240mg IV every 2 weeks monotherapy</description>
    <arm_group_label>Nivolumab Monotherapy</arm_group_label>
    <arm_group_label>Nivolumab/BMS-986253 combination</arm_group_label>
    <arm_group_label>Nivolumab/Cabiralizumab combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have histologically confirmed evidence of HCC, Childs-Pugh score of ≤7.&#xD;
&#xD;
             a. Participants must be willing to provide specimen from fresh, pre- and on-treatment&#xD;
             tumor core biopsies for histologic diagnosis and translational studies.&#xD;
&#xD;
          2. Radiographically measurable disease by RECIST1.1 in at least one site.&#xD;
&#xD;
          3. Deemed to not be a candidate for resection or other local-regional therapy.&#xD;
&#xD;
          4. Must not be receiving treatment with other investigational agents and must not have&#xD;
             received any other systemic therapy prior to registration.&#xD;
&#xD;
             a. Prior radioembolization, local ablative therapies (radiofrequency, microwave or&#xD;
             cryoablation), radiation (external beam or stereotactic), or hepatic resection&#xD;
             permitted if completed ≥ 4 weeks prior to study enrollment and if patient has&#xD;
             recovered with ≤ grade 1 toxicity and if untreated measurable disease is present.&#xD;
&#xD;
          5. Be willing and able to provide written informed consent/assent for the trial.&#xD;
&#xD;
          6. Participants must be ≥ 18 years&#xD;
&#xD;
          7. Have a Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          8. If hepatitis B is present, participants must be on anti-viral HBV therapy.&#xD;
&#xD;
          9. All women of childbearing potential (not surgically sterilized and between menarche&#xD;
             and 1 year post menopause) must have a blood test to rule out pregnancy within 24&#xD;
             hours prior to start of study treatment&#xD;
&#xD;
         10. All women of childbearing potential must agree to follow instructions for method(s) of&#xD;
             contraception for the duration of treatment with study treatment (s) and for 5 months&#xD;
             following discontinuation of study treatment.&#xD;
&#xD;
         11. Males who are sexually active with women of childbearing potential must agree to&#xD;
             follow instructions for method (s) of contraception for the duration of treatment with&#xD;
             study treatment and for 7 months following discontinuation of study treatment.&#xD;
             Additionally, male participants must not donate sperm during this period.&#xD;
&#xD;
         12. Demonstrate adequate organ function as defined by the following required lab and&#xD;
             acceptable range criteria:&#xD;
&#xD;
        Adequate bone marrow function:&#xD;
&#xD;
        Absolute neutrophil count &gt; 1000/mcL Platelet count &gt; 50,000/mcL Hemoglobin &gt; 8.5 g/dL&#xD;
&#xD;
        Adequate hepatic function:&#xD;
&#xD;
        Total bilirubin &lt; 2 mg/dL or &lt; 1.5 times upper limit of normal (ULN) AST and ALT &lt; 5 times&#xD;
        ULN INR &lt; 1.5 times ULN Albumin &gt; 2.8 g/dL&#xD;
&#xD;
        Adequate renal function:&#xD;
&#xD;
        Creatinine &lt; 2.0 mg/Dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant or breastfeeding.&#xD;
&#xD;
          2. Presence of other malignancies. Participants with active second malignancy other than&#xD;
             non-melanoma skin cancer or cervical carcinoma in situ. NOTE: Patients with history of&#xD;
             malignancy are not considered to have a &quot;currently active&quot; malignancy if they have&#xD;
             completed therapy and are now considered by their physician to be at less than 30%&#xD;
             risk for relapse.&#xD;
&#xD;
          3. Have active or history of Tuberculosis&#xD;
&#xD;
          4. Participants with known HIV positive status&#xD;
&#xD;
          5. Participants with known CNS metastases&#xD;
&#xD;
          6. Uncontrolled ascites&#xD;
&#xD;
          7. Uncontrolled encephalopathy&#xD;
&#xD;
          8. Uncontrolled gastro-esophageal varicesPrior organ allograft or allogeneic bone marrow&#xD;
             transplantation&#xD;
&#xD;
          9. Participants with active, known, or suspected autoimmune disease. Participants with&#xD;
             vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune&#xD;
             condition only requiring hormone replacement, euthyroid participants with a history of&#xD;
             Grave's disease (participants with suspected autoimmune thyroid disorders must be&#xD;
             negative for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating&#xD;
             immunoglobulin prior to first dose of study treatment), psoriasis not requiring&#xD;
             systemic treatment, or conditions not expected to recur in the absence of an external&#xD;
             trigger are permitted to enroll.&#xD;
&#xD;
         10. Participants with a condition requiring systemic treatment with either corticosteroids&#xD;
             (&gt; 10 mg daily prednisone equivalents) or other immunosuppressive medications within&#xD;
             14 days of study treatment administration except for adrenal replacement steroid doses&#xD;
             &gt; 10 mg daily prednisone equivalent in the absence of active autoimmune disease. Note:&#xD;
             Treatment with a short course of steroids (&lt; 5 days) up to 7 days prior to initiating&#xD;
             study treatment is permitted.&#xD;
&#xD;
         11. Interstitial lung disease that is symptomatic or may interfere with the detection or&#xD;
             management of suspected treatment-related pulmonary toxicity.&#xD;
&#xD;
         12. Uncontrolled or significant cardiovascular disease including, but not limited to, any&#xD;
             of the following:&#xD;
&#xD;
               -  Myocardial infarction or stroke/transient ischemic attack within the past 6&#xD;
                  months&#xD;
&#xD;
               -  Uncontrolled angina within the past 3 months&#xD;
&#xD;
               -  Any history of clinically significant arrhythmias (such as ventricular&#xD;
                  tachycardia, ventricular fibrillation, or torsades de pointes)&#xD;
&#xD;
               -  History of other clinically significant heart disease (eg, cardiomyopathy,&#xD;
                  congestive heart failure with New York Heart Association functional&#xD;
                  classification III to IV, pericarditis, significant pericardial effusion, or&#xD;
                  myocarditis)&#xD;
&#xD;
               -  Cardiovascular disease-related requirement for daily supplemental oxygen therapy.&#xD;
&#xD;
         13. Participants with ongoing or active, uncontrolled infections (afebrile for ≥ 48 hours&#xD;
             off antibiotics). If hepatitis B is present, must be on anti-viral HBV therapy.&#xD;
&#xD;
         14. Must not have a psychiatric illness, other significant medical illness, or social&#xD;
             situation which, in the investigator's opinion, would limit compliance or ability to&#xD;
             comply with study requirements.&#xD;
&#xD;
         15. Any major surgery within 4 weeks of study treatment. Participants must have recovered&#xD;
             from the effects of major surgery or significant traumatic injury at least 14 days&#xD;
             before&#xD;
&#xD;
         16. Any uncontrolled inflammatory disease including Crohn's disease and ulcerative colitis&#xD;
&#xD;
         17. Treatment with botanical preparations (eg, herbal supplements, including potential&#xD;
             drugs of abuse, or traditional Chinese medicines) intended for general health support&#xD;
             or to treat the disease under study within 2 weeks prior to randomization/treatment.&#xD;
&#xD;
         18. Concomitant use of statins while on study.&#xD;
&#xD;
         19. Current or history of clinically significant muscle disorders (eg, myositis), recent&#xD;
             unresolved muscle injury, or any condition known to elevate serum CK levels.&#xD;
&#xD;
         20. Known history of sensitivity to infusions containing Tween 20 (polysorbate 20) and&#xD;
             Tween 80 (polysorbate 80).&#xD;
&#xD;
         21. Participants who have received a live / attenuated vaccine within 30 days of first&#xD;
             treatment.&#xD;
&#xD;
         22. Concomitant use of any live / attenuated vaccine during treatment and until 100 days&#xD;
             following last dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theodore Welling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edward Chin</last_name>
    <phone>917-502-7366</phone>
    <email>Edward.Chin@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Chin</last_name>
      <email>Edward.Chin@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Theodore Welling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Karasic, MD</last_name>
      <email>Thomas.Karasic@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Karasic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

